| Similar Articles |
|---|
 |
The Motley Fool
February 14, 2005
Stephen D. Simpson |
Glaxo Stays Above the Fray The British drugmaker looks to regain momentum this year. Investors who are comfortable with the general industry risks and are looking for a relatively "clean" pharmaceutical company should do some research on Glaxo shares.   |
The Motley Fool
April 22, 2011
Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
The Motley Fool
February 8, 2008
Brian Lawler |
Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper. |
The Motley Fool
February 8, 2006
Stephen D. Simpson |
Glaxo: Healthy Drugmaker Glaxo combines a huge sales force, a rich pipeline, and solid returns on capital. This company should get a thorough look from anyone putting new money into the pharma space. |
The Motley Fool
October 28, 2004
Bill Mann |
Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year. |
The Motley Fool
July 26, 2006
Stephen D. Simpson |
GlaxoSmithKline: Reliable, Dependable ... Kinda Boring This is a good-but-not-great pharmaceutical giant with a good-but-not-great valuation. Investors, take note. |
The Motley Fool
April 29, 2010
Brian Orelli |
Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business. |
The Motley Fool
December 1, 2005
Brian Gorman |
Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note. |
The Motley Fool
July 28, 2005
Stephen D. Simpson |
Glaxo Keeps It Going Despite missing sales from the depression franchise, Glaxo managed to post respectable quarterly results. |
The Motley Fool
June 13, 2008
Brian Lawler |
Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval. |
The Motley Fool
April 28, 2005
Stephen D. Simpson |
Glaxo Works to Stay on Track With FDA issues near resolution, Glaxo should continue its respectable growth trajectory. Investors looking at the pharmaceutical space would do well to at least consider this stock. |
The Motley Fool
October 18, 2005
Stephen D. Simpson |
More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note. |
The Motley Fool
November 9, 2006
Brian Lawler |
The Best Blue Chip for 2007: GlaxoSmithKline Here's a blue-chip pharma stock for your portfolio. |
The Motley Fool
February 12, 2004
Alyce Lomax |
Depressing Year for Glaxo The pharmaceutical giant forecasts three lackluster quarters as copycats attack. |
The Motley Fool
May 4, 2006
Stephen D. Simpson |
AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch. |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after. |
The Motley Fool
November 30, 2009
Brian Orelli |
Making Money More Efficiently Drug companies shape up, and it shows in their margins. |
The Motley Fool
November 26, 2007
Brian Lawler |
Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year. |
The Motley Fool
February 22, 2010
Brian Orelli |
Warning: Avandia Could Cause Drool Among Trial Lawyers An unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers. A 342-page report by the Senate Finance Committee is painting the diabetes drug in a not-so-great light. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
September 25, 2006
Brian Lawler |
Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note. |
The Motley Fool
June 23, 2010
Kris Eddy |
Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
January 21, 2010
Brian Orelli |
The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments. |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
Glaxo's Story Still Worth Reading A good pipeline could keep GlaxoSmithKline's already-impressive shares rolling. |
The Motley Fool
October 28, 2009
Brian Orelli |
Saved by Emerging Markets. Sort Of. GlaxoSmithKline's top line looks good, but the bottom is what counts. |
The Motley Fool
May 8, 2009
Brian Orelli |
Glaxo Goes Head-to-Head on HPV Glaxo's data may not be enough to help Cervarix knock Merck's Gardasil from the top papillomavirus vaccine spot. |
The Motley Fool
February 5, 2009
Brian Orelli |
Glaxo Cuts Jobs, Guidance -- and the Kitchen Sink With sales dropping, more cuts were inevitable. |
The Motley Fool
July 25, 2008
Brian Lawler |
Glaxo Changes Course Will a shift in strategy turn the drugmaker around? |
The Motley Fool
March 2, 2010
Brian Orelli |
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. |
The Motley Fool
December 31, 2007
Brian Lawler |
Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma. |
The Motley Fool
April 28, 2008
Brian Lawler |
Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers. |
The Motley Fool
October 30, 2007
Charly Travers |
Winners and Losers in Big Pharma Some drugmakers are hitting a slump, but not all of them. Which ones can still cure what ails your portfolio? |
The Motley Fool
February 29, 2008
Brian Orelli |
2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed. |
The Motley Fool
October 23, 2007
Brian Orelli |
Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter. |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
September 11, 2008
Brian Orelli |
Glaxo's Not Gambling The pharmaceutical's deal for drug developer Cellzome is back-end loaded. |
The Motley Fool
July 7, 2009
Brian Orelli |
Glaxo Missed the Boat The HPV vaccine market is declining before Glaxo can hop aboard. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
April 24, 2006
Stephen D. Simpson |
Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions. |
The Motley Fool
February 26, 2010
Brian Orelli |
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. |
The Motley Fool
April 16, 2009
Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
The Motley Fool
July 1, 2008
Brian Lawler |
FDA News Gives Glaxo a Glimmer of Hope Approval is delayed, but new studies won't be needed for Cervarix. |
The Motley Fool
June 14, 2007
Ryan Fuhrmann |
Dueling Fools: GlaxoSmithKline Bear Glaxo is definitely a safe bet in the industry, and Avandia concerns have brought the share levels to even more reasonable levels. But investors can find the risk/reward trade-off even more compelling in other names. |
The Motley Fool
January 10, 2012
Sean Williams |
2012 Preview: Merck The biggest question mark facing the pharmaceutical behemoth in 2012 is just how badly it will be affected by losing patent-exclusivity rights on its biggest drug, Singulair. |
The Motley Fool
February 26, 2010
Brian Orelli |
Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market. |
The Motley Fool
February 3, 2011
Owain Bennallack |
Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks. |
The Motley Fool
April 20, 2006
Stephen D. Simpson |
Wait for More Bad News on Merck Vioxx lawsuits will be an ever-present headline risk for a while, but I still believe it's highly unlikely that they'll do lasting damage to the business. That said, the nearly 30% rise in this stock since late '05 has taken a lot of the easy money off the table. |
The Motley Fool
December 24, 2009
Brian Orelli |
Another Reason to Worry About Pfizer The FDA fails to approve Lyrica for treating anxiety. |
